Current approaches to the treatment of Parkinson's disease

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 4, 2008, Pages 743-757

  Jankovic, Joseph ^a   Aguilar, L Giselle ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Deep brain stimulation; Levodopa; Medical treatment; Pallidotomy; Parkinson's disease

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE; BENZATROPINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ETILEVODOPA; ETIRACETAM; FIPAMEZOLE; FLUOXETINE; LEVODOPA; LEVODOPA METHYL ESTER; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NABILONE; PERGOLIDE MESILATE; PLACEBO; PRAMIPEXOLE; PROPRANOLOL; ROPINIROLE; ROTIGOTINE; TOLCAPONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; AGITATION; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COMPULSION; CONTINUOUS INFUSION; DELUSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSKINESIA; HALLUCINATION; HUMAN; HYPERSEXUALITY; HYPOTENSION; IMPULSE CONTROL DISORDER; INSOMNIA; LIVER FAILURE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PALLIDOTOMY; PARANOIA; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERIPHERAL EDEMA; PSYCHOSIS; REVIEW; SIDE EFFECT; SKIN IRRITATION; SLEEP DISORDER; SOMNOLENCE; SPEECH THERAPY; THALAMOTOMY; TREATMENT DURATION; VOMITING;

EID: 52649164155     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s2006     Document Type: Review

References (164)

1. Allain H, Cougnard J, Neukirch HC, et al. 1991. Selegilene in de novo parkinsonian patients: the French selegiline multicenter trial. Acta Neurol Scand, 136:73-8.
2. Anderson VC, Burchiel KJ, Hogarth P, et al. 2005. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol, 62:554-60.
3. Assal F, Spahr L, Hadengue A, et al. 1998. Tolcapone and fulminant hepatitis. Lancet, 19:958.
4. Barone I, Rektor I, Bares M, et al. 2003. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol, 10:399-406.
5. Baronti F, Davis TL, Boldry RC, et al. 1992. Deprenyl effects on levodopa pharmacodynamics, mood and free radical scavenging. Neurology, 42:541-4.
6. Bejjani BP, Gervais D, Arnulf I, et al. 2000. Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry, 68:595-600.
7. Bhatia KP, Münchau A, Brown P. 1999. Botulinum toxin is a useful treatment in excessive drooling of saliva. J Neurol Neurosurg Psychiatry, 67:697.
8. Blindauer K, and the Parkinson Study Group. 2003. Delayed response to levodopa and response failures account for a large percentage of daily off time in advanced Parkinson's disease patients with motor fluctuations. Neurology, 60:81-2.
9. Bonnet AM. 2000. Involvement of non-dopaminergic pathways in Parkinson's disease. Pathophysiology and therapeutic implications. CNS Drugs, 13:351-64.
10. Borek LL, Chou KL, Friedman JH. 2007. Management of the behavioral aspects of Parkinson's disease. Expert Rev Neurother, 7:711-25.
11. Breier A, Sutton VK, Feldman PD, et al. 2002. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry, 52:438-45.
12. Brodsky MA, Godbold J, Roth T, Olanow CW. 2003. Sleepiness in Parkinson's disease: A controlled study. Mov Disord, 18:668-72.
13. Brooks DJ. 2000. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry, 68:685-90.
14. Burchiel KJ, Anderson VC, Favre J, et al. 1999. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advances Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery, 45:1375-84.
15. Ceravolo R, Nuti A, Piccini A, et al. 2000. Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. Neurology, 55:1216-8.
16. Chase TN, Oh JD. 2000. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. TINS, 23:86-91.
17. Cristina S, Zangaglia R, Mancini F, et al. 2003. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol, 26:146-50.
18. Cummings JL. 1992. Depression and Parkinson's disease: a review. Am J Psychiatry, 149:443-54.
19. Diamond A, Jankovic J. 2005. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry, 76:1188-93.
20. Diamond A, Shahed J, Jankovic J. 2007. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci, 260:199-203.
21. Dodd ML, Klos KJ, Bower JH, et al. 2005. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol, 62:1377-81.
22. Driver-Dunckley E, Samanta J, Stacy M. 2003. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology, 61:422-3.
23. Dujardin K, Sockeel P, Devos D, et al. 2007. Characteristics of apathy in Parkinson's disease. Mov Disord, 22:778-84.
24. Ellison RH. 1998. Dear health professional letter regarding appropriate use of Tasmar. Nutley, NJ: Roche Laboratories Inc.
25. Emre M, Aarsland D, Albanese A, et al. 2004. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med, 351:2509-18.
26. Etminan M, Gill S, Samii A. 2003. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 26:439-44.
27. Evans AH, Katzenschlager R, Paviour DC, et al. 2004. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord, 19:397-405.
28. Fabbrini F, Barbanti P, Aurilia C, et al. 2002. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci, 23:41-3.
29. Factor SA, Feustel PJ, Friedman JH, et al. 2003. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology, 60:1756-61.
30. Fahn S. 2000. The spectrum of levodopa-induced dyskinesias. Ann Neurol, 47:2-11.
31. Fénelon G, Mahieux F, Huon R, Ziégler M. 2000. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain, 123:733-45.
32. Fernandez HH, Trieschmann ME, Friedman JH. 2003. Treatment of psychosis in Parkinson's disease; safety considerations. Drug Saf, 26:643-59.
33. Food and Drug Administration. 1998. New Warnings for Parkinson's Drug Tasmar. Rockville, MD. November 16, T98-81.
34. Friedman JH, Berman RM, Goetz CG, et al. 2006. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord, 21:2078-81.
35. Friedman JH, Chou KL. 2004. Sleep and fatigue in Parkinson's disease. Parkinsonism Relat Disord, 10:27-35.
36. Friedman JH, Factor SA. 2000. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord, 15:201-11.
37. Friedman JH. 1994. Punding on levodopa. Biol Psychiatry, 36:350-1.
38. Frucht S, Rogers JD, Greene PD, et al. 1999. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology, 52:1908-10.
39. Gagnon JF, Postuma RB, Montplaisir J. 2006. Update on pharmacology of REM sleep behavior disorder. Neurology, 67:742-7.
40. Gash DM, Zhang Z, Gerhardt G. 1998. Neuroprotective and neurorestorative properties of GDNF. Ann Neurol, 44:121-5.
41. Giladi N, McDermott MP, Fahn S, et al; and the Parkinson Study Group. 2001. Freezing of gait in PD. Prospective assessment of the DATATOP cohort. Neurology, 56:1712-21.
42. Gill SS, Patel NK, Horton GR, et al. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med, 9:589-95.
43. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. 2005. Use of ziprasidone in patients with psychosis. Clin Neuropharmacol, 28:111-4.
44. Grandas F, Hernandez B; PRACTICOMT Study Group. 2007. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. Eur J Neurol, 14:282-9.
45. Grünblatt E, Mandel S, Berkuzki T, et al. 1999. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord, 14:612-8.
46. Haberler C, Alesch F, Mazal PR, et al. 2000. No tissue damage by chronic deep brain stimulation in Parkinson's disease. Ann Neurol, 48:372-6.
47. Hariz MI, Johansson F, Shamsgovara P, et al. 2000. Bilateral subthalamic nucleus stimulation in a parkinsonian patient with preoperative deficits in speech and cognition: Persistent improvement in mobility but increased dependency: A case study. Mov Disord, 15:136-9.
48. Hauser RA, Wahba MN, Anderson WM. 2000. Modafinil treatment of pramipexole-associated somnolence. Mov Disord, 15:1269-71.
49. Hauser RA. 2004. Levodopa/carbidopa/entacapone (Stalevo). Neurology, 62:64-71.
50. Heikkinen H, Varhe A, Lyly V, et al. 2003. New levodopa, carbidopa and entacapone combination tablets. European J Neurology, 10: 164.
51. Henderson JM, Pell M, O'Sullivan DJ, et al. 2002. Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Mov Disord, 17:133-7.
52. Hill MP, Bezard E, Brotchie JM, et al. 2003. The antiepileptic, levetiracetam (Keppra), modulates the process of priming for L-dopa-induced dyskinesia in MPTP-lesioned marmosets. European J Neurology, 10: 164.
53. Jankovic J, Watts RL, Martin W, et al. 2007. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol, 64:676-82.
54. Jankovic J. 1999. New and emerging therapies for Parkinson's disease. Arch Neurol, 56:785-90.
55. Jankovic J. 2000. Parkinson's disease therapy: Tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol, 23:252-61.
56. Jankovic J. 2001. Surgery for Parkinson's disease and other movement disorders: Benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol, 58:1970-2.
57. Jankovic J. 2002. Levodopa strengths and weaknesses. Neurology, 58: 19-32a.
58. Jankovic J. 2002. Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E, (eds.) Parkinson's Disease and Movement Disorders, 4th edition, Philadelphia, PA: Lippincott Williams and Wilkins. p116-151b.
59. Jankovic J. 2005. Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations. Mov Disord, 11: 11-6.
60. Jankovic J. 2008a. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry, 79:368-76.
61. Jankovic J. 2008b. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol, 63:267-9.
62. Jankovic J. Stacy M. 2007. Medical management of levodopa-associate motor complications in patients with Parkinson's disease. CNS Drugs, 21:677-92.
63. Jouvent R, Abensour P, Bonner AM, et al. 1983. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. J Affect Disord, 5:141-5.
64. Kompoliti K, Wang QE, Goetz CG, et al. 2000. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology, 54:458-62.
65. Korczyn AD, Brunt ER, Larsen JP, et al. 1999. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology, 53:364-70.
66. Korczyn AD, Thalamas C, Adler CH. 2002. Dosing with ropinirole in a clinical setting. Acta Neurol Scand, 106:200-4.
67. Kordower JH, Herzog CD, Dass B, et al. 2006. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol, 60:706-15.
68. Krack P, Batir A, Van Blercom N, et al. 2003. Five-year followup of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med, 349:1925-34.
69. Krauss JK, Jankovic J, Grossman RG, eds. 2001. Surgery for Movement Disorders, Philadelphia, PA: Lippincott Williams and Wilkins. p 1-449.
70. Kumar R, Lozano AM, Sime E, et al. 1999. Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. Neurology, 53:561-6.
71. Kurlan R. 2004. Disabling repetitive behaviors in Parkinson's disease. Mov Disord, 19:433-69.
72. Lang AE, Gill S, Patel NK, et al. 2006. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson's disease. Ann Neurol, 59:459-66.
73. Le W-D, Jankovic J. 2001. Are dopamine agonists neuroprotective in Parkinson's disease? J Drugs and Aging, 18:389-96.
74. Lees AJ, Katzenschlager R, Head J, et al. 2001. Ten-year follow up of three different initial treatments in de-novo PD. A randomized trial. Neurology, 57:1687-94.
75. Lees AJ, Ratziu V, Tolosa E, et al. 2007. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J Neurol Neurosurg Psychiatry, 78:944-8.
76. LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. 2007. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology, 68:1262-7.
77. Linazasoro G, Van Blercom N, Lasa A. 2003. Unilateral subthalamic deep brain stimulation in advanced Parkinson's disease. Mov Disord, 18:713-6.
78. Luck GC, Brown RG. 2002. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry, 73:636-42.
79. Lucking CB, Durr A, Bonifati V, et al. 2000. Association between early onset Parkinson's disease and mutations in the parkin gene. New Engl J Med, 342:1560-67.
80. Luginger E, Wenning GK, Bösch S, et al. 2000. Beneficial effects of amantadine on dopa-induced dyskinesias in Parkinson's disease. Mov Disord, 15:873-8.
81. Mancini F, Tassorelli C, Martignoni E, et al. 2004. Long term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson's disease. Clin Neuropharmacol, 27:33-7.
82. Manson AJ, Turner K, Lees AJ. 2002. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow up study of 64 patients. Mov Disord, 17:1235-41.
83. Marks WL, Verhagen Metman L, Starr P, et al. 2006. Neurturin gene transfer for Parkinson's disease: motor outcomes from the initial CERE-120 clinical trial. Mov Disord, 21:608.
84. Marras C, Lang AE. 2003. Measuring motor complications in clinical trials for early Parkinson's disease. J Neurol Neurosurg Psychiatry, 74:143-6.
85. Merims D, Balas M, Peretz C, et al. 2006. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol, 29:331-7.
86. Miyasaki JM, Al Hassan & Lang AE, et al. 2007. Punding prevalence in Parkinson's disease. Mov Disord, 22:1179-81.
87. Miyasaki JM, Shannon K, Voon V, et al. 2006. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review). Report of the subcommittee of the American Academy of Neurology. Neurology, 66:996-1002.
88. Nakao N, Nakai T, Nakai K, et al. 1999. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann Neurol, 45:640-51.
89. Nutt JG, Burchiel KJ, Comella CL, et al. 2003. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology, 60:69-73.
90. Nutt JG, Carter JH. 2000. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD. Neurology, 54:247-50.
91. Nutt JG. 2007. Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? Mov Disord, 22:1-9.
92. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. 2000. Pathophysiology of the basal ganglia in Parkinson's disease. TINS, 23:8-19.
93. Olanow CW, Tasmar Advisory Panel. 2000. Tolcapone and hepatotoxic effects. Arch Neurol, 57:263-67.
94. Ondo W, Hunter C, Almaguer M, et al. 1999. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol, 22:1-4a.
95. Ondo W, Hunter C, Almaguer M, et al. 1999. Sublingual apomorphine in patients with fluctuating Parkinson's disease. Mov Disord, 14:664-8b.
96. Ondo W, Jankovic J, Schwartz K, et al. 1998. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology, 51:1063-9.
97. Ondo WG, Fayle R, Atassi F, et al. 2005. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry, 76:1636-9b.
98. Ondo WG, Levy JK, Vuon KV, et al. 2002. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord, 17:1031-5.
99. Ondo WG, Tintner R, Dat Voung K, et al. 2005. Double blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord, 20:958-63a.
100. Ondo WG, Wong KV, Khan H, et al. 2001. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology, 57:1392-6.
101. Pact V, Giduz T. 1999. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology, 53:1154.
102. Pal PK, Calne DB, Calne S, et al. 1999. Botulinum-A toxin in the treatment of sialorrhea in patients with Parkinson's disease. Parkinsonism Relat Disord, 5:82.
103. Parkinson Study Group. 2002. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 287:1653-61.
104. Parkinson Study Group. 2003. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol, 60:1721-8.
105. Parkinson Study Group. 2005. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol, 62:241-8.
106. Pereira da Silva-Junior F, Braga-Neto P, Sueli Monte F, et al. 2005. Amantadine reduces the duration of levodopa-induced dyskinesia: A randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord, 11:449-52.
107. Pietz K, Hagell P, Odin P. 1998. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry, 65:709-16.
108. Pillon B, Ardouin C, Damier P, et al. 2000. Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology, 55:411-8.
109. Poewe W, Leussi F. 2005. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology, 65:11-4.
110. Poewe W, Wenning GK. 2000. Apomorphine: An underutilized therapy for Parkinson's disease. Mov Disord, 15:789-94.
111. Rabey JM, Prokhorov T, Miniovitz A, et al. 2007. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord, 22:313-8.
112. Rajput AH, Fenton ME, Birdi S, et al. 2002. Clinical pathological study of levodopa complications. Mov Disord, 17:289-96.
113. Rascol O, Brooks DJ, Korczyn AD, et al. 2000. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med, 18:1484-91.
114. Rascol O, Brooks DJ, Melamed E, et al; LARGO study group. 2005. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet, 365:947-54.
115. Ravina B, Camicioli R, Como PG, et al. 2007. The impact of depressive symptoms in early Parkinson's disease. Neurology, 69:342-7.
116. Reading PJ, Luce AK, McKeith U, et al. 2001. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord, 16:1171-95.
117. Reisberg B, Doody R, Stoffler A, et al; Memantine Study Group. 2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med, 348:1333-41.
118. Rektorova I, Rektor I, Bares M, et al. 2003 Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre perspective randomized study. Eur J Neurol, 10:399-406.
119. Reyner LA, Horne JA. 1998. Falling asleep whilst driving: are drivers aware of prior sleepiness? Int J Legal Med, 111:120-3.
120. Rich SS, Friedman JH, Ott BR. 1995. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry, 56:556-9.
121. Richard IH. 2005. Anxiety disorders in Parkinson's disease. Adv Neurol, 96:42-55.
122. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. 2005. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow up. Brain, 128:2240-9.
123. Roth BL. 2007. Drugs and valvular heart disease. N Engl J Med, 356:6-9.
124. Ruottinen HM, Rinne UK. 1998. COMT inhibition in the treatment of Parkinson's disease. J Neurol, 245:25-34.
125. Saint-Cyr JA, Trepanier LL, Kumar R. et al. 2000. Neuropsychologic consequences of chronic bilateral stimulation of the STN in Parkinson's disease. Brain, 123:2091-108.
126. Schapira AH, Olanow CW. 2004. Neuroprotection in Parkinson's Disease: mysteries, myths and misconceptions. JAMA, 291:358-64.
127. Schrag A, Schott JM. 2006. Epidemiological, clinical and genetic characteristics of early-onset parkinsonism. Lancet Neurol, 5:355-63.
128. Schrag A. 2005. Entacapone in the treatment of Parkinson's disease. Lancet Neurol, 4:366-70.
129. Schrag AS, Quinn N. 2000. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain, 123:2297-305.
130. Schuurman PR, Bosch A, Bossuyt PMM, et al. 2000. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med, 342:461-8.
131. Shiba M, Bower JH, Maragnore DM, et al. 2000. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord, 15:669-77.
132. Shoulson I, Oakes D, Fahn S, et al. 2002. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol, 51:604-12.
133. Shults CW, Oakes D, Kieburtz K, et al. 2002. Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol, 59:1541-50.
134. Simpkins N, Jankovic J. 2003. Neuroprotection in Parkinson's disease. Arch Int Med, 163:1650-4.
135. Starkstein SE, Mayberg HS, Preziosi TJ, et al. 1992. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci, 4:134-9.
136. Stein MB, Heuser IJ, Juncos JL, et al. 1990. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry, 147:217-20.
137. Stern MB, Marek KL, Friedman J, et al. 2004. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord, 19:916-23.
138. Stern MB. 2004. Dopamine agonists modify the course of Parkinson disease. Arch Neurol, 61:1969-71.
139. Stocchi F, Vacca L, Berardelli A, et al. 2003. Dual dopamine agonist treatment in Parkinson's disease. J Neurol, 250:822-6.
140. Stocchi F, Vacca L, Ruggieri S, et al. 2005. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol, 62:905-10.
141. Stover NP, Bakay RA, Subramanian T, et al. 2005. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol, 62:1833-7a.
142. Stover NP, Okun MS, Evatt ML, et al. 2005. Stimulation of the subthalamic nucleus in a patient with Parkinson disease and essential tremor. Arch Neurol, 62:141-3b.
143. Takeshita S, Kurisu K, Trop L, et al. 2005. Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of previous facts and problems. Neurosurg Rev, 28:179-86.
144. Tan EK, Ondo W. 2000. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol, 57:729-32.
145. Tandberg E, Larsen JP, Aarsland D, et al. 1996. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol, 54:175-9.
146. Tintner R, Manian P, Gauthier P, et al. 2005. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease. Arch Neurol, 62:1290-5.
147. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, et al. 1993. "Panic attacks" in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol Scand, 87:14-8.
148. Verhagen Metman L, Dotto PD, LePoole K, et al. 1999. Amantadine for levodopa-induced dyskinesias. A 1-year follow up study. Arch Neurol, 56:1383-6.
149. Verhagen Metman L, Konitsiotis S, Chase TN. 2000. Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what. Mov Disord, 15:3-8.
150. Voon V, Thomsen T, Miyasaki JM, et al. 2007. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol, 64:212-6.
151. Voon V. 2004. Repetition, repetition and repletion: compulsion and punding behaviors in Parkinson's disease. Mov Disord, 19:367-70.
152. Watts RL, Jankovic J, Waters C, et al. 2007. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology, 68:272-6.
153. Watts RL, Raiser CD, Stover NP, et al. 2003. Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. J Neural Transm Suppl, 65:215-27.
154. Weiner WJ, Factor SA, Jankovic J, et al. 2001. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord, 7:115-20.
155. Weiner WJ. 2004. Initial treatment of Parkinson disease: levodopa or dopamine agonists. Arch Neurol, 61:1966-9.
156. Weintraub D, Stern WB. 2007. Intervening in the neuropsychiatric features of Parkinson's disease. Expert Rev Neurother, 7:699-710.
157. Whone AL, Watts RL, Stoessl AJ, et al. 2003. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol, 54:93-101.
158. Wilkinson DG, Passmore AP, Bullock R, et al. 2002. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract, 56:441-6.
159. Williams-Gray CH, Foltynie T, Lewis SJG, et al. 2006. Cognitive deficits and psychosis in Parkinson's disease: A review of Pathophysiology and therapeutic options. CNS Drugs, 20:477-505.
160. Wolozin B, Wang SW, Li NC, et al. 2007. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med, 19:5-20.
161. Zanettini R, Antonini A, Gatto G, et al. 2007. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New Eng J Med, 356:39-46.
162. Zesiewicz TA, Gold M, Chari G, et al. 1999. The occurrence of depression in Parkinson's disease. Arch Neurol, 53:175-9.
163. Zhang SM, Hernan MA, Chen H, et al. 2002. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology, 59:1161-9.
164. Zou L, Jankovic J, Rowe DB, et al. 1999. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci, 64:1275-85.